AlixaRx

About AlixaRx

AlixaRx operates as a national institutional pharmacy provider, focusing on the post-acute and long-term care market within the United States. The company was founded in 2012 by private investment firm Fillmore Capital Partners to address inefficiencies in medication management for healthcare facilities. The business concept was in development for four years prior to its formal launch, originating within Drumm Corp., the holding company for Fillmore Capital Partners' healthcare companies. In July 2013, AlixaRx was spun off from Drumm Corp. with a $100 million capitalization to support its growth and technology development.

The company's business model integrates technology and clinical pharmacy services to manage medication therapy for patients in settings like skilled nursing facilities. AlixaRx provides on-site, proprietary automated dispensing systems and electronic medication cabinets that give healthcare facilities 24/7 access to over 400 medications, including oral solids, liquids, IVs, and refrigerated items. This on-demand dispensing of daily supplies contrasts with traditional pharmacy models that use 7, 15, or 30-day punch cards, a method AlixaRx states can reduce drug costs for facilities by 8-10% as they are only billed for what is used. Revenue is generated by providing these comprehensive pharmacy services, which include the dispensing technology, medications and supplies, and clinical pharmacist consulting.

A key component of AlixaRx's service is its team of board-certified, geriatric-specialty clinical pharmacists who collaborate with a facility's care team. These pharmacists have real-time electronic access to patient information, allowing them to optimize drug therapy, reduce the number of medications consumed, and improve patient safety. The company also operates a Medication Review and Optimization Center (MROC) for prospective analysis of high-acuity residents. Headquartered in Plano, Texas, AlixaRx services its clients through several regional pharmacy hubs located across the country in cities such as Minneapolis, Kansas City, Indianapolis, Pittsburgh, and Fresno. In 2021, the company agreed to a $2.75 million settlement to resolve allegations from the Department of Justice regarding the improper dispensing of controlled substances and violations of the Controlled Substances Act between 2014 and 2017.